CRC

EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
수요일, 3월 13, 2024

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Key Points: 
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration
    BERKELEY, US – MAINZ, Germany – March 5, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a partnership with Trusted Health Advisors (THA), a market leader in supporting the U.S. launches and management of commercial programs for diagnostic products.
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.

EQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Retrieved on: 
수요일, 3월 13, 2024

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Key Points: 
  • Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
    BERKELEY, US – MAINZ, Germany – March 12th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany.
  • Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.
  • For more details on Mainz Biomed’s participation in the UDH Congress and to learn about the Company’s innovative diagnostic solutions, please visit Mainz Biomed’s official website at mainzbiomed.com .

EQS-News: Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Retrieved on: 
수요일, 3월 13, 2024

BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.
  • TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan.
  • "TomaLab is the ideal partner to bring our pioneering product to Italy given its state-of-the-art facilities and commitment to innovative healthcare solutions, " said Guido Baechler, CEO of Mainz Biomed.
  • "We are thrilled to collaborate with Mainz Biomed to incorporate ColoAlert® into our laboratory procedures."

Canter Resources Receives NOI Approval and Exploration Well Permit for the Columbus Lithium-Boron Project

Retrieved on: 
수요일, 3월 6, 2024

The Company has also received its permit from the Nevada Division of Minerals for its initial exploration well at the Columbus Lithium-Boron Project ("Columbus") located near Tonopah, Nevada.

Key Points: 
  • The Company has also received its permit from the Nevada Division of Minerals for its initial exploration well at the Columbus Lithium-Boron Project ("Columbus") located near Tonopah, Nevada.
  • "With our permits and approved NOI in place at Columbus we have reached another key milestone and are now in position to finalize our engagements with contractors and ramp up field activities," stated Joness Lang, CEO of Canter.
  • These regulatory milestones pave the way for Canter to launch its Phase I exploration program, designed to rapidly assess the lithium and boron mineral resource potential within the Columbus Basin.
  • Dirt work will commence concurrently with drill site preparation for the Company's first exploration well.

Canter Resources Closes Final Tranche of Its Non-Brokered Private Placement

Retrieved on: 
화요일, 3월 5, 2024

Vancouver, British Columbia--(Newsfile Corp. - March 5, 2024) - Canter Resources Corp. (CSE: CRC) (OTC Pink: CNRCF) (FSE: 6O1) ("Canter" or the "Company") is pleased to announce that has closed the final tranche of its non-brokered private placement raising gross proceeds of $250,000 through the issuance of 500,000 units (the "Units") at $0.50 per Unit (the "Offering").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 5, 2024) - Canter Resources Corp. (CSE: CRC) (OTC Pink: CNRCF) (FSE: 6O1) ("Canter" or the "Company") is pleased to announce that has closed the final tranche of its non-brokered private placement raising gross proceeds of $250,000 through the issuance of 500,000 units (the "Units") at $0.50 per Unit (the "Offering").
  • Joness Lang, CEO and a director of the Company purchased 37,000 Units in the Offering.
  • Mr. Lang also purchased 125,000 Units in the first tranche for a combined total of 162,000 Units.
  • The Company paid finder's fees of $7,000 cash and 14,000 finder's warrants (the "Finder's Warrants") in connection with the closing of the final tranche of the Offering.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
월요일, 3월 11, 2024

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
월요일, 3월 11, 2024

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

United in the Fight Against Colorectal Cancer

Retrieved on: 
목요일, 3월 7, 2024

A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.

Key Points: 
  • A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.
  • Despite these escalating rates, there has been a lack of progress in developing effective treatment options for colorectal cancer patients, and persistent health disparities in incidence, mortality, and survivorship rates continue to exist.
  • United in Blue serves as a visual reminder for policymakers, emphasizing the necessity of increasing research funding for colorectal cancer and implementing a comprehensive plan to address the needs of the community.
  • Fight CRC’s United in Blue installation is sponsored by Amgen and Exact Sciences.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
목요일, 3월 7, 2024

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Retrieved on: 
수요일, 3월 6, 2024

MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases.

Key Points: 
  • MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases.
  • This includes the tumor antigens that present due to liver metastases, as the liver shuts down the anti-cancer T cell response.
  • Consequently, liver metastases pose a significant challenge for current pharmacological treatments, including immune checkpoint inhibitors (ICIs).
  • iNKT cells offer promise in overcoming this immune barrier, given their natural ability to reside in and migrate to the liver.